Nitrase Therapeutics
Sami is a senior scientist at Nitrome Biosciences where he is currently developing the HTS assays for measuring the activity of the novel enzymes and the compounds that will inhibit them. After working in genomics on the Human Genome Project and DNA microarray technologies at Affymetrix, he transitioned to small molecule and antibody drug discovery at Exelixis, Renovis, iPierian, True North Therapeutics, Bioverativ, and currently at Nitrome Biosciences. His efforts in research, development, and clinical assay transfers have contributed to the successful progress of four clinical drug candidates so far: EVT-401, a small molecule P2X7 receptor antagonist for rheumatism; IPN007, a tau antibody for PSP and Alzheimer’s Disease; and BIVV009/BIVV020, complement C1s antibodies for Cold Agglutinin Disease and other autoimmune blood disorders. He studied genetics and molecular and cell biology at UC Berkeley and Stanford.
This person is not in any offices
Nitrase Therapeutics
1 followers
Nitrase Therapeutics is a pioneering biopharmaceutical company deploying its unique NITROME platform to unlock the therapeutic potential of nitrases, a new class of enzymes that it discovered, to develop a pipeline of therapies against a broad variety of diseases. The medicines that Nitrase Therapeutics is developing will target these enzymes and potentially help slow or halt the progression of a wide variety of diseases in which nitrases and nitro-substrates play a role, including Parkinson’s and cancer. Nitrase Therapeutics (under the former name Nitrome Biosciences) has been widely recognized and has won multiple awards including the prestigious Target Advancement grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF).